Podcast appearances and mentions of Charles River

A recent proposal by the Massachusetts Water Resources Authority (MWRA) would allow sewage overflows into the Charles River by declassifying it as “safe to swim,” a designation that allows the waterway to be “occasionally subject to short-term impairment of swimming or other recreational uses.” The MWRA was set to vote on the proposal but tabled the vote. It's unclear how they will proceed but advocates of keeping the Charles River, Alewife Brook, and other local waterways sewage free view the postponement as a victory. Emily Norton, the executive director of the Charles River Watershed Association joined to discuss the ongoing concerns over proposed sewage overflows into the Charles River.See omnystudio.com/listener for privacy information.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with: Andrew Gigax, Head of European Pharma Services M&A at William Blair Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting Sabina Ouimet Storrs, Principal at GHO Capital Partners Jason Foss, Head of Corporate Development at Bora Pharmaceuticals Your host, Raman Sehgal, speaks with his guests about the pharmaceutical and biotechnology ecosystem, including: How market stabilisation has been overtaken by the need for adaptation in times of uncertainty Disciplined and deeper M&A, with heightened scrutiny, buyer and seller disconnect, and a sharper focus on operational efficiency The growing demand for bispecifics, radiopharma, isotopes, and other emerging segments Why the “picks and shovels” that serve multiple modalities are where opportunity lies in pharma services Why the US remains the hottest market, and how AI adoption has mainly focused on workflow so far The shifts and trends that could reshape pharma services in the years ahead Molecule to Market is sponsored by Bora Pharma, Charles River and Lead Candidate, and supported by Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

The Boston Globe's Nancy Barnes and Shirley Leung join for “Press Play" media analysis. The talk about AI in journalism, new polls about Americans' trust in media, and the 2025 Globe Summit. GBH's Callie Crossley discusses a bill on book banning, new lousy polling numbers for President Trump and Cheryl Hines' new memoir.Shelter Music Boston performs for Live Music Friday. They're celebrating 15 years of performing in local homeless shelters. We talk with founder Julie Levin, founding violist Rebecca Strauss and managing director Carrie Eldridge-DicksonNBC10 Boston's Sue O'Connell recaps her trip to Canada reporting on the Christmas tree cutting ceremony. Plus, SCOTUS declining to hear case to overturn same-sex marriage and an alligator in the Charles River.

A baby alligator was found along the Charles River and someone falls for potentially the worst scam attempt in Essex in the New England Nightly News.

With the Patriots now in action, we have some fun starting with tonight's Headlines featuring the announcement of AL and NL MVP and NFL owners deflecting blame by wanting to get rid of the NFLPA survey. Then, a baby alligator was found in the Charles River while an Essex scammer had the basic way of scamming an elderly man in the New England Nightly News. And, an update on the Patriots and Bruins who have done a great job of limiting penalties.

In this episode of Molecule to Market, your host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Jean-François Brepson, Chief Executive Officer at PathoQuest. The conversation covers: Navigating 20 years of global leadership roles at Ipsen before moving from the corporate world into an investor-led entrepreneurial adventure The tough decision to refocus PathoQuest from diagnostics into a pure play CRO and pharma services business How a major strategic partnership transformed the company's trajectory and why Jean sees partnerships as a competitive weapon Riding the tailwind of the FDA's move away from animal testing and offering something game-changing in the CMC and GMP space The opportunities ahead for CROs and CDMOs in helping unlock the next wave of innovation Jean-François Brepson is a dedicated leader with deep experience in biotechnology and pharmaceuticals. Since becoming CEO of PathoQuest in 2015, he has built the company into a leading global CRO specializing in quality control of biological drugs using Next Generation Sequencing (NGS). Over his career, he has advanced innovative technologies and solutions that bridge scientific progress with real-world application. Prior to joining PathoQuest, Jean was Senior Vice President at Ipsen, where he led the global GI-Oncology and Endocrinology franchise.   Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

The Smithsonian Museums and other institutions reopen after the government shutdown, the Charles River alligator is on the road to recovery and Watertown police shuts down six spas. Stay in "The Loop" with WBZ NewsRadio.See omnystudio.com/listener for privacy information.

A caller shocks everyone when he reveals he has six kids with six different women — oh, and he’s a tattoo artist.

Millions of Americans wait for their SNAP benefits, with the government re-opened. The country's Roman Catholic bishops criticize the Trump administration over its immigration policies. The alligator found in the Charles River has been rescued. Stay in "The Loop" with WBZ NewsRadio.See omnystudio.com/listener for privacy information.

The government shutdown ends on day 43, no more wild alligators in the Charles River, and Starbucks baristas goes on strike on Red Cup Day. Stay in "The Loop" with WBZ NewsRadio.See omnystudio.com/listener for privacy information.

WBZ NewsRadio's Brooke McCarthy has more.See omnystudio.com/listener for privacy information.

The vote to end the government shutdown, an alligator spotted in the Charles River, and disruptions at Logan Airport continues. Stay in "The Loop" with WBZ NewsRadio.See omnystudio.com/listener for privacy information.

We knew it was Dirty Water but an Alligator in the Charles?? People are looking for a small alligator that was spotted over the weekend...

The Bubonic Plague, Yersinia Pestis, arrives in London at the end of 1664. By the end of 1665, it will have killed 200,000 people all across England and Wales. Evelyn Lord, The Great Plague: A People's History. Dorothy Moote, The great plague: the story of London's most deadly year. Charles River, The Great Plague of London: The History and Legacy of England's Last Major Outbreak of the Bubonic Plague Rebecca Rideal, 1666: Plague, War, and Hellfire. Learn more about your ad choices. Visit megaphone.fm/adchoices

Keith Crawford, Global Head of Corporate Development and M&A at State Street Corporation Keith Crawford, Global Head of Corporate Development and M&A at State Street Corporation, brings over 20 years of expertise executing some of the most intricate custody business carve-outs in financial services. In this episode, Keith breaks down the realities of carve-out transactions—from proactive deal sourcing and dependency mapping to navigating TSAs and post-close integration. He shares hard-won lessons on avoiding common pitfalls like scope creep, third-party contract renegotiations, and employee retention challenges that can derail even the most promising deals. Things You'll Learn Why carve-out transactions demand bespoke approaches: No two deals are alike—discover how to identify the 20% of unknowns that templates can't capture and build flexibility into your diligence process. How to source carve-out opportunities proactively: Learn State Street's strategy for targeting custody business carve-outs, including the "why us" narrative and who to approach (hint: not the business unit leader). The integration secrets that prevent deal failure: From embedding integration experts early in diligence to managing employee retention and TSA timelines, Keith reveals how to align synergy assumptions with operational reality. ____________________ Share Your M&A Experience for the Chance at $500 Giftcard M&A moved fast in 2025. But what actually changed? We're collecting real insights from practitioners—not consultants on the sidelines—to understand how corp dev teams, PE firms, and advisors are adapting. Takes 10 min. Get early access to results + chance at $500 gift card. Share your experience: https://hubs.ly/Q03Rr89G0 ____________________ This episode is brought to you by S&P Global. Today's episode of M&A Science is brought to you by S&P Global Market Intelligence. If you're in corp dev or PE, you know the pain — good private company data is hard to come by. Everyone's still chasing clean, reliable, up-to-date data. I started out using CapIQ Pro for public comps, but didn't realize until recently how deep their private company coverage has gotten. Over 58 million private companies, global reach, and actually usable for real deal work.  This isn't surface-level. You get real metrics — ownership, financials, funding rounds, even asset-level insights. So if you're still toggling between a dozen tools trying to piece together the picture, maybe it's time to stop guessing and start sourcing better.  Learn More Here: https://www.spglobal.com/market-intelligence/en/solutions/products/private-company-data?utm_source=podcast&utm_medium=video&utm_campaign=MAScienceH225 _______________ Episode Chapters: [00:03:30] From Accountant to M&A Leader – Keith's journey from audit to becoming a dealmaking general contractor [00:06:00] The General Contractor Mindset – Why successful M&A requires orchestrating expert teams across tax, operations, IT, and risk [00:06:30] The 80/20 Rule of Carve-Outs – Why templates work for most deals but the 20% whitespace requires bespoke analysis [00:10:00] Third-Party Contract Landmines – How change-of-control provisions can blow up your valuation assumptions [00:16:00] Building Strategic Alignment Early – Embedding integration experts into diligence to bridge deal models with operational reality [00:23:00] Proactive Deal Sourcing Strategy – State Street's approach to targeting custody business carve-outs with a clear "why us" narrative [00:35:00] Leveraging Banker Networks Strategically – How mid-tier investment banks often have better contacts for carve-out opportunities [00:48:00] Culture Preservation in Integration – Lessons from the Charles River acquisition on maintaining employee morale and retention [00:52:30] Major Deal Breakers – The two red flags that cause State Street to walk away from carve-out transactions [00:55:00] The Craziest M&A Moment – A hospital room negotiation that almost derailed a major international carve-out ____________________ Questions, comments, concerns?Follow Kison Patel for behind-the-scenes insights on modern M&A.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jason Anderson, Chief Executive Officer at Ensera.   Your host, Raman Sehgal, speaks with Jason about the pharmaceutical and biotechnology supply chain, covering: Why he chose BASF over law school, and why McKinsey ultimately was not for him Moving from corporate life into a venture-backed polymer technology start-up before a major exit The search for a PE-backed specialty manufacturing role that led him to Ensera (formerly SteriPack) The importance of appreciating local knowledge when entering new markets Similarities and differences between outsourced services in pharma and medical devices How today's changes, pain, and uncertainty in the markets are creating opportunity Jason Anderson is CEO of Ensera (formerly SteriPack), a global contract design and manufacturing organization serving the pharmaceutical and medical device industries. He has led the company through a period of significant growth and change, including the integration of new design and product development capabilities with Ensera's core manufacturing services, and the launch of the new Ensera trading name.   Prior to Ensera, Jason held global business unit leadership roles at DJO/Enovis and at Saint-Gobain, overseeing businesses ranging from finished medical devices to customized, high-value components for biopharma and medical device industries. Earlier in his career, he held leadership roles at pre-revenue polymer technology start-up Novomer, at McKinsey and Company, and at BASF.   Jason has lived and worked in North America, Asia, and Europe. He holds a BS in Chemical Engineering from the University of Oklahoma and an MBA from Harvard Business School.   Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

Charles River scientist Nicole Hoekstra, herself a US Navy veteran, used her employer-supported sabbatical to help out local Oklahoma based nonprofit Inner Circle Mental Health, which focuses on aiding veterans and first responders who are struggling with their mental health. I am joined by Nicole and ICMH founder Kate Cooper to discuss what this service means to both of them, how we can support family who are reluctant to accept help, and how the COVID pandemic impacted the mental health of first responders. 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with our host Raman Sehgal, who discusses the themes and vibe of CPHI 2025 in Frankfurt.     Molecule to Market is also sponsored by Bora Pharma and Charles River, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll hear wily old wisdom, golden nuggets and invaluable insider tips about CPHI. The nuanced stuff from Veterans of CPHIs gone by you'll never find in a generic AI-written playbook. The show features: James West, Managing Director, Bourne Partners Arul Ramadurai, CCO at Axplora Christine Fuerst, Director Key Account Management Europe, Vetter Pharma International GmbH Dan Stanton, leading pharma/biopharma industry journalist  Jeremy Drummond PhD, retired VP Sales and Marketing Exec.   Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Gil Roth, President, at Pharma & Biopharma Outsourcing Association (PBOA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering: How planned FDA budget cuts and the ongoing US government shutdown are impacting the industry. And the potential outlook if those issues remain unresolved... Why positive early-phase clinical trial activity could signal a stronger year ahead Real-life applications of AI and machine learning for GMP in CDMOs through signal and pattern recognition Why Gil is feeling more optimism across the CDMO community And yes… you can also see Gil and Raman together on stage at the industry's very own “Super Bowl” of conferences Gil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference. Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called The Virtual Memories Show (https://chimeraobscura.com/vm).   Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with JB Agnus, Chief Commercial Officer at Bora Pharmaceuticals. Your host, Raman Sehgal, speaks with JB about the pharmaceutical and biotechnology supply chain, including: How his global roles taught him the importance of bridging cultures What attracted him to Bora Pharmaceuticals and the company's remarkable trajectory The value of intentionality, taking charge of your own career, and prioritising physical and mental wellness What it really looks and feels like to be a CDMO CCO, and the realities of stepping up into the role Why it matters not to conform to the norm and instead stay true to yourself Prior to joining Bora, JB held senior leadership roles in business development at AGC Biologics, Ajinomoto Bio Pharma Services, Novasep, and Isochem. He holds a bachelor's degree in organic chemistry from Université Paul Sabatier Toulouse III in Toulouse, France, and a master's degree in chemical engineering from Centrale Méditerranée in Marseille, France.   Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

In 2025, the Head of the Charles regatta celebrates 60 years - so we thought it was a perfect opportunity to reflect and look ahead at this event that brings together thousands of rowers and fans to the shores of the Charles River in Boston. We're incredibly honored to talk with D'Arcy MacMahon, one of three original founders of the regatta AND Fred Schoch, whose tenure as regatta executive director stretched 33 years. We've paired these two legends together to explore the vision of the founders and the stewardship of that vision over the last six decades. QUICK LOOK 00:00 - Episode intro and welcome 03:53 - Rowing Week 05:41 - The Huddle 08:22 - Hot Seat Q&A 13:24 - D'Arcy's fun childhood racing at CBC was the inspiration for HOCR 16:44 - Fred's youth was dominated by time at the Princeton boathouse where his Dad was coach 19:22 - D'Arcy and Fred are no strangers to racing at HOCR 22:46 - The true life (and death) story of a made up man: Charles Attager 25:14 - D'Arcy is dumbfounded by the longevity and growth of HOCR 30:23 - On carrying the legacy forward 32:30 - Setting the course in 1965 with D'Arcy's mom's bike odometer 36:36 - Volunteer spirit of service (starts with a great t-shirt) 39:12 - Support from the MDC, Massachusetts, and corporate sponsors 42:18 - Getting results: taking a cue from golf's leaderboards  43:39 - HOCR and the community 45:40 - Growing the  international field, and considering travel logistics for all crews 50:38 - Best place to watch the races 52:05 - Head of the Charles Charity 52:49 - Spirit of the regatta: fun! 54:24 - Steady State Network news and notes . To see photos of D'Arcy, Fred, and the Head of the Charles, and get links to the people, clubs, and events mentioned in this episode, check out the show notes on our website. . This episode was made possible in part by Breakwater Realty, RowSource, and our Supporters. . Steady State Podcast is hosted and edited by Rachel Freedman and Tara Morgan. Tara provides additional audio engineering, books show guests, and is our sponsor and donor coordinator. Rachel writes our scripts and e-newsletter, and manages the website and social media. Our theme music is by Jonas Hipper. . SHOP SSN GEAR: www.steadystatenetwork.com/shop SIGN UP FOR THE SSN NEWSLETTER: www.steadystatenetwork.com/newsletter MAKE A DIFFERENCE: www.steadystatenetwork.com/support  Check out more Steady State Network here:  FB - /SteadyStateNetwork IG - @SteadyStateNetwork BLUESKY - steadystatenetwork.bsky.social FB - /AllieswithOars IG - @AllieswithOars Connect on FB and IG with the hosts: Rachel Freedman - @RowSource Tara Morgan - @CmonBarber

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Philip Macnabb, Chief Executive Officer at Curia. Your host, Raman Sehgal, speaks with Phil about the pharmaceutical and biotechnology supply chain, covering: Over 25 years of working with private equity — and why PE is ultimately about building sustainable value. The common threads he looks for as a CEO of any new organisation, and why employees often know the answer first. Navigating the COVID comedown at Curia, making major network changes, and refocusing on biotech clients. Why CDMOs are really selling trust as the service, not just manufacturing — and how that plays into customer intimacy and reputation. Betting on the trend toward small batch sizes and personalised medicines in biotech and pharma. Phil leads Curia in pursuit of its mission to improve patients' lives, applying end-to-end capabilities and deep scientific expertise to advance customers from idea to impact. He brings more than 20 years of private-equity leadership experience to Curia, including the last decade in healthcare. Most recently, he served as Chief Executive Officer at Epsilon Global, a company he co-founded. In addition to his healthcare experience, he has held senior positions in technology, distribution, and consumer products. Phil has a proven track record of sharpening companies' core value proposition, enhancing the customer experience, and building organisations with real, lasting value. Phil earned an MBA from the University of Chicago and a BS in Business Administration from Purdue University.   Molecule to Market is sponsored by Bora Pharma and Charles River, and supported by Lead Candidate. Please subscribe, tell your colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Lars Petersen, President & Chief Executive Officer at FUJIFILM Biotechnologies.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lars, covering: The difficult decision to leave Novo Nordisk and make the jump from one great company to another in Genentech/Roche. How leaving a Biogen site led him to step away from big pharma after 25 years and transition to the CDMO side. How Fujifilm's culture of innovation, technology, quality, and people runs through the Biotechnologies division — and why empowerment and culture should never be compromised. Why the duplication of its CDMO sites globally, all running on the same kojoX platform, is truly differentiating. Why he believes the need to standardise, scale, and globalise drug production in a consistent, efficient, and traceable way is key to the future of the supply chain. Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate.    Lars Petersen, CEO of FUJIFILM Biotechnologies, is recognized as a visionary leader in the life science sector, commanding a global contract development and manufacturing organization (CDMO) with nearly 5,000 employees spread across Denmark, UK, USA, and Japan.    Distinguished for his strategic vision and a "people first" philosophy, Lars has profoundly impacted the company and the industry. His leadership journey saw him rise from Chief Operational Officer & Senior Vice President at the Danish site, where he established an empowering culture, to CEO, promoting transparency across all operations. Since his global leadership appointment in June 2023, Lars has been instrumental in cultural transformation, integrating a "people first" approach across FUJIFILM Biotechnologies' global facilities regardless of geographical differences.   Prior to his appointment as CEO, Lars was responsible for the Global Large Scale Commercial operation including full profit and loss accountability as well as the responsibility for over $6.2 Billion global expansions both in Hillerød, Denmark, and Holly Springs, North Carolina, USA.   Previously, Lars has held leadership positions with Biogen, Genentech/Roche, Novo Nordisk, Novozymes and NNE, and he has successfully executed projects in Europe, China and the US.   Lars holds a master's degree from the Technical University of Denmark.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Matt Lowe, CEO at performance.io/ Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Matt, covering: Seeing a niche in SEO, within the healthcare space... and opting to take a risk and jump our of big pharma. Why healthcare agency models are built for agencies, not pharma. The mass wastage of big pharma spend when it comes to the commercial launch. How you should be thinking about generative search and customer experience... and why Google is still dominating the search landscape. Founder and CEO at performance-io (PIO), Matt has been the driving force behind bringing search engine optimization (SEO) into pharma. With more than 22 years in the highly regulated industry pharma space, spanning client-side and agency roles, he is responsible for a number of industry firsts, all focused on helping pharma companies to revolutionize their customer engagement.   Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Michael Scholl, Chief Executive Officer and Co-Founder at Leukocare. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Michael, covering: The influences, and potential for impact that led him down a path of entrepreneurship. Chronicling the ups and downs of over 20 years in business at Leukocare. Pivoting to be a specialist CRO/CDMO with a differentiation in data-driven, formulation development... leading to a record year in 2024. How the delay in decision making in the market is impacting the pharma services space. Michael Scholl is the Co-founder and Chief Executive Officer of Leukocare, a leading CDMO specializing in formulation and drug product development services for sterile injectables. With more than 20 years of leadership experience in the life sciences industry, Michael is responsible for shaping the company's strategic direction and cultivating partnerships with biopharmaceutical clients around the world. Under his leadership, Leukocare has established itself as a trusted partner in advancing complex biologics from early development to market-ready drug products. He began his career as a business consultant at the Boston Consulting Group (BCG), he holds a degree in Industrial Engineering from the Technical University of Berlin and studied at the Haas School of Business, University of California, Berkeley.   Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Kaan-Fabian Kekec, Partner in Healthcare and Life Sciences at Simon-Kucher. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kaan, covering: Being on the sunny side of consulting, and helping clients unlock growth. What makes a key strategic partnership both from a CDMO, and a sponsor perspective. The taboo subject of pricing and how it can be used to help unlock commercial positioning, and excellence. Common mistakes in BD teams, and the importance of value positioning. The hottest segments in the market right now, and some of the competitive drivers in today's market. Kaan leads the firm's Healthcare B2B and Pharma Services business globally, encompassing CDMOs, CROs, bioprocessing solutions, drug delivery, packaging, and more. He specializes in delivering end-to-end commercial strategies for CDMOs, advising on growth initiatives and supporting clients throughout the entire lead-to-deal process—from marketing and sales to proposal management and deal optimization. Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.  Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

What does it really take to qualify for the Boston Marathon? Grit? Speed? A fast course? How about… running the same loop ten times in a row? This past Sunday, Amy ran the Charles River Invitational, a 2.6 mile loop around the Charles River.  Same scenery. Not much crowd support. Pouring rain. One last shot on the last day to qualify for Boston for 2026.  We break down the strategy- from pacing to nutrition; what it felt like to run the same loop over and over; and why Boston is still the mecca of all marathons out there for runners!   

Boston is one of those cities that just gets under your skin in the best way possible. Equal parts old-school history and modern-day hustle, it's where cobblestone streets meet glass skyscrapers, where the story of America was born, and where you can eat your body weight in lobster rolls without a shred of regret.Founded in 1630 by English Puritans, Boston has played host to some of the most pivotal events in U.S. history—the Boston Tea Party, the Battle of Bunker Hill, and even the first public park in America. Today, it's a vibrant mix of college-town energy, cutting-edge innovation, and diehard sports fandom (you'll never hear a “Go Sox!” shouted with more passion than here).I recently spent five days exploring Boston like a local, armed with a loose plan, comfy walking shoes, and an appetite big enough to conquer the city's legendary food scene. Here's how it all went down—my perfect Boston adventure. Day 1: Arrival & First Taste of the CityFlying into Logan International Airport is a breeze—it's practically right in the city. But here's your first Boston pro-tip: skip renting a car if you can. Boston traffic is next-level chaotic, parking is expensive, and the city is surprisingly walkable. Between the subway (locals call it “the T”) and Uber, you'll get around just fine.Of course, I had to test the rental car waters—$368 for two days of a Nissan Rogue—and let me tell you, the line alone made me question my life choices. If you do rent, book with a company that lets you walk straight to the garage and grab your car. Otherwise, hop in an Uber and save yourself the headache.Where to StayI split my stay between two totally different vibes:Hampton Inn & Suites Watertown – Budget-friendly ($100 a night) and great if you don't mind being just outside the city. Parking in Boston can run you $30 a day, so staying here helped balance the budget.Copley Square Hotel (FOUND Hotels) – Right in the heart of Back Bay, this historic gem ranges from $300–$600 a night. My corner-view studio overlooked the breathtaking Trinity Church at sunset, and it felt like waking up inside a postcard. Designed in 1877 by architect H.H. Richardson, this place is dripping with Richardsonian Romanesque charm—arched windows, rough stone, and colorful details. Around Copley, you'll also find:Fairmont Copley Plaza (1912) – A Gilded Age beauty and part of the Historic Hotels of America.Boston Public Library McKim Building (1895) – A Renaissance Revival masterpiece with white marble halls and free daily tours at 2 pm. Don't skip it; the architecture is jaw-dropping.Old South Church (1873) – A National Historic Landmark in Northern Italian Gothic style, complete with multicolored stone and a towering bell.John Hancock Tower (1976) – Boston's tallest skyscraper at 790 feet, shimmering in blue glass.After a long travel day, we celebrated our first night with dinner at Lolita Cocina & Tequila Bar. Order the lobster guacamole and grilled elote—and when in Boston, remember the golden rule: always order seafood. Steaks are for later. Oh, and if you see Scrod on the menu? Don't panic. It's not a weird mythical fish; it's just the white catch of the day—usually cod or haddock. Day 2: Walking Through HistoryIf Boston had a greatest hits album, it would be the Freedom Trail—a 2.5-mile path that connects 16 historic sites and tells the story of America's revolution. You can do it self-guided, join a regular tour, or go all out with an actor-led adventure (think Paul Revere cosplay).Morning Coffee & Boston CommonStart with caffeine at Thinking Cup Coffee Bar, then wander into Boston Common, the oldest public park in America (1634). It's massive, filled with monuments, and now home to the striking Embrace Memorial, honoring Martin Luther King Jr.From there, the trail unfolds like a time machine:Massachusetts State House (1798) – Charles Bulfinch's golden-domed wonder, still home to the state government.Park Street Church (1809) – Once Boston's tallest landmark, it sits on the site of the city's old grain storage.Granary Burying Ground (1660) – Final resting place of heavyweights like John Hancock, Sam Adams, and Paul Revere.King's Chapel & Burying Ground (1686) – Boston's first Anglican church, with over 330 years of history.Boston Latin School Site (1635) – The oldest public school in America; today it's marked by a Benjamin Franklin statue.Old Corner Bookstore (1718) – Once the publishing hub of legends like Hawthorne, Longfellow, and Thoreau. Now… a Chipotle (I wish I were kidding).Lunch at Union Oyster HouseBy now, you'll be starving. Enter Union Oyster House, America's oldest continuously operating restaurant (since 1826). The JFK booth is a must-sit, and yes—you're ordering a lobster roll.Afternoon: Monuments & Baseball MagicDon't miss the New England Holocaust Memorial—six glass towers etched with survivor stories, both sobering and moving.Then, if you're lucky enough to visit in season, cap off your night at Fenway Park. Whether it's catching a Red Sox game, snagging early batting practice passes, or just soaking up the energy at Cask 'n Flagon across the street (hot tip: persistence pays when getting a table here), Fenway is pure Boston. Day 3: More Freedom Trail & North End TreatsStart with breakfast at Quincy Market, the ultimate food hall. Then dive back into history:Old South Meeting House (1729) – Where colonists debated tea taxes and kicked off the Boston Tea Party.Old State House (1713) – Boston's oldest public building, central to colonial politics.Boston Massacre Site (1770) – A simple cobblestone marker for one of America's darkest sparks of revolution.From here, pop back into Quincy Market for another lobster roll (yes, it's worth a second one).Keep following the trail:Faneuil Hall (1742) – “Cradle of Liberty” where fiery speeches once filled the air. Today, it's mostly a giant souvenir shop, but the echoes of history remain.Paul Revere House (1680) – The patriot's humble home. Tours are intimate but no photos allowed inside.Old North Church (1723) – Where lanterns signaled “One if by land, two if by sea.” Take the tour to see the crypt and bell chamber.Cannoli TimeBoston's North End is an Italian dreamland, so refuel at Mike's Pastry with a giant cannoli. (Pro tip: get a few extra to-go. You'll thank me later.)End the night at Bell in Hand Tavern (1795), America's oldest continuously operating tavern. It's rowdy, it's historic, and it's the perfect spot for your nightcap. Day 4: Big Battles & Big ShipsIf your legs aren't jelly yet, tackle the Bunker Hill Monument. Climb the 294 steps for killer views of the city.From there, wander over to the USS Constitution, aka “Old Ironsides,” the oldest commissioned warship afloat. The ship and museum are free and make for an epic history-meets-maritime adventure.For a modern twist, hop in an Uber to the JFK Presidential Library & Museum—a sleek, inspiring deep dive into the Camelot era. Afterward, head to Sam Adams Brewery in Jamaica Plain. Tours start at $10, include tastings, and give you all the Boston beer vibes. Day 5: Art, Rainy-Day Magic & Sunset on the HarborBoston weather can turn on a dime, so I saved indoor treasures for day five.Morning: Museum of Fine ArtsThe MFA is massive, so choose wisely:Jewelry lovers: Beyond Brilliance exhibit (ancient to modern sparkle, with Chanel and Bulgari highlights).Classicists: Greek, Roman, and Byzantine collections.Painters-at-heart: Dutch & Flemish gallery with works by Rembrandt and Rubens.Quirky souls: Dollhouses and temporary Van Gogh exhibits.Fuel up at the museum café before heading out.Evening: Sunset Harbor CruiseOur trip ended on the water, with a Boston Harbor sunset cruise. Even in the rain, the top deck views were worth it. There's a buffet dinner, DJ, and plenty of space to dance—because no Boston trip is complete without one last celebration. Other Boston Must-Dos (If You Have Time)Duck Boat Tour – Amphibious buses that roam the streets then splash into the Charles River. Cheesy? Yes. Fun? Also yes.Cheers Pub – Grab a drink where everybody used to know your name.Green Dragon Tavern – A revolutionary haunt turned modern-day pub.Boston Burger Co. or Wahlburgers – Because you need at least one outrageous burger on this trip. Final ThoughtsBoston is the kind of city that can be done in a weekend but deserves a week. It's history you can touch, seafood you'll crave long after, and neighborhoods that feel like they've been waiting just for you.If you only had one day, I'd say walk the Freedom Trail—it's Boston in a nutshell. But if you want to experience the city like a local? Take your time, eat the lobster rolls, get lost in the cobblestone streets, and maybe—just maybe—let Fenway turn you into a Red Sox fan for life.Boston, you're wicked awesome.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adam Siebert, Managing Director and Partner at L.E.K. Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering: Adam's journey from academic to commercial, and what helped him transition into 'life science enablers". How pandemic demand has left our sector with a huge over capacity issue and market imbalance. Some positive signals for the second half of 2025 after a period of geopolitical chaos, and a bumpy rollercoaster. Even thought biotech funding has largely returned... how decreasing clinical trials, a shifting of therapeutic focus, and the concentration of investments on fewer, higher value deals is impacting pharma services. The value of building a reputation in one in-demand modality area before extending into other modalities. And why the CDMO is at an inflexion point... Adam is a Managing Director and Partner in L.E.K. Consulting's New York office and a member of the Life Sciences practice. He has been with L.E.K. for over eight years, and has experience across diagnostics and research tools, bioprocessing and pharma services, and emerging, mid-cap and large pharma. Adam has helped a number of clients in the life sciences industry with growth strategy, life cycle management, portfolio optimization and M&A projects. Adam holds a Bachelor of Science from Boston College and a Ph.D. from the Perelman School of Medicine at the University of Pennsylvania.    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Stephen Dilly, Chairman, President and Chief Executive Officer at Codexis. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Stephen, covering: His journey of almost 40 years in the industry, including 20 years as a CEO. Leading two therapeutic companies to two, successful, $billion+ exits... Not making snap judgements and instant opinions early on in your role as a senior leader. Why he took on the challenge of leading Codexis at this phase of his career. The importance of values as guiding principles, and spending in-person time with your team. As President & CEO of Codexis since August 2022, Stephen brings more than three decades of executive management experience in the biopharmaceutical industry. Most recently, he served as President and CEO of Sierra Oncology (NASDAQ: SRRA) through its recent sale to GlaxoSmithKline for $1.9 billion.  Previously, Dr. Dilly served as CEO of Aimmune Therapeutics, acquired by Nestle Health Science for $2.6 billion. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development, approval and launch of more than twenty marketed drugs across multiple therapeutic areas. He holds both an MBBS and a PhD in Cardiac Physiology from the University of London.   Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Tara Dougal, Event Director - Pharma (CPHI Europe). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tara, covering: How CPHI has changed over the last decade of Tara being involved in the show. The challenge of dealing with the volume of over 60k people turning up for three days at a major European city. Being tasked with running one of Informa Markets' largest global shows. How to make the most of this year's CPHI Europe before, during and after the show. The hidden gems of opportunity that you might be missing out on at CPHI. Tara brings over 12 years of extensive event management experience spanning roles in New York, London, and Amsterdam. She previously held the position of Content Director before advancing to her current leadership role. Her expertise extends beyond event management to content production, where she has demonstrated exceptional skill in creating high-quality content and building strategic relationships with clients and partners. At CPHI, Tara plays a crucial role in creating connections and inspiring partnerships across the global pharmaceutical community, championing innovation at the heart of pharma through both in-person and online events. Her international experience and industry insight contribute significantly to Informa Markets' position as the world's leading exhibitions organiser, delivering over 550 market-leading events annually.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

In the first episode of Season 4 of The Object of History, we briefly discussed the filling in of the Charles River bay when we introduced listeners to the Historical Society's building at 1154 Boylston Street. On this bonus episode, we invited one of our 2025 Dean W. Eastman Undergraduate Library Residents, Vivienne Charpentier, to dive deeper into history of the Back Bay. Vivienne tells us more about the Back Bay and then joins Chief Historian Peter Drummey on a walking tour of the neighborhood. Learn more about episode objects here: https://www.masshist.org/podcast/season-4-bonus-episode-Back-Bay  Email us at podcast@masshist.org. Listen to "1154 Boylston Street". Episode Special Guest: Vivienne Charpentier was a Dean W. Eastman Undergraduate Library Resident in the 2025 Academic Year. They will begin their master's program in Library & Information Studies at the University of Rhode Island in the fall of 2025. This episode uses materials from: Canoe by Podington Bear (Attribution-NonCommercial 3.0 International)        Psychic by Dominic Giam of Ketsa Music (licensed under a commercial non-exclusive license by the Massachusetts Historical Society through Ketsa.uk)        Curious Nature by Dominic Giam of Ketsa Music (licensed under a commercial non-exclusive license by the Massachusetts Historical Society through Ketsa.uk)

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Andrea Wagner, CEO at PharmaPhixx. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andrea, covering: Building a 'not very pretty' business, to an eventual exit after 10 years The reluctant founding of Berkshire Sterile Manufacturing (Now Sharp)...making new mistakes on her encore journey of growth and a second exit Why company leaders should think of decision-making like trees Pro business development tips from a seasoned entrepreneur with growth hard-wired into her Her views on the current market and what opportunities lie ahead for the brave Dr. Andrea N. Wagner is a serial entrepreneur renowned for co-founding and advancing two contract sterile manufacturing companies, with her latest venture acquired by Sharp Services in October 2023. She passionately advocates for women in business, serving on the board of Women Entrepreneurs Grow Global (WEGG), co-founding Herizon Funding to support women-owned businesses, and contributing as an advisory board member at the Boston Museum of Science. As CEO of PharmaPhixx and founder of the sweater brand LuxLined in 2024, Andrea continues to diversify her business interests. Additionally, she established the Andrea Wagner Scholarship Fund to support young women pursuing STEM degrees. Currently, she is writing a book, focusing on empowering women in STEM to ascend to leadership roles. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

How do researchers keep our dirt clean? How can earthworms, duckweed, birds and bees help us ensure environmental safety? Find out now by listening in with our experts from Charles River's Hungarian site - Szabolcs Gáty and David Esdaile.

A waring is out from the City of Boston to avoid part of the Charles River, police in Montana are searching for a gunman who killed four people at a bar, and the big college move-in day is under a month away.

The White House said times up to cut a tariff deal, federal court denied Boston Marathon bomber's appeal, and harmful algae bloom closed off the Charles River. Stay in "The Loop" with WBZ NewsRadio. 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adam Sherlock, CEO at Qinecsa. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering: How he developed his professional CEO skills over the years to complement is entrepreneurial spirit The combination of micro and macro factors that help determine when the right time is to go to market, and sell The importance of your gut instinct when assessing M&A targets... and painting a picture of why the world is a better place when together Several attempts at failing to retire... and being tempted back into another pharma services CEO role How R&D services will be impacted by AI, and why we all need to be eating our own lunch Adam is a serial entrepreneur and executive leader with nearly 40 years of experience in the international life sciences industry, particularly in bio/pharma, IVD, and medical device sectors. A scientist by training, he has led successful growth and M&A efforts, creating exceptional value in four private equity-backed businesses over the past decade.  Adam is also a sought-after NED, Chair, and independent advisor. Currently, he serves as CEO of Qinecsa, a global provider of pharmacovigilance technology and services. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

In this special episode of Molecule to Market, recorded at this year's CDMO Live in Rotterdam, industry leaders come together to assess the evolving state of the contract development and manufacturing sector. Raman is the panel moderator, joined by:  Gil Roth - PBOA Dr. Jim Li - BioDuro Sundia Kaan-Fabian Kekec - Simon-Kucher They unpack cautious optimism in the face of lingering market uncertainties and geopolitical tension, you'll hear: How CDMOs are adapting to early-stage funding strain and evolving pricing models The impact of rising interest rates, tariffs, and global trade policy on pharma outsourcing Capacity and talent constraints facing CDMOs in new therapeutic modalities Why integrated models and scenario planning are key to future-proofing operations This episode offers timely insight into the challenges and opportunities shaping the next phase of growth for CDMOs worldwide. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

No Café com Investidor, Camilo Marcantonio, fundador da Charles River Capital, explica sua tese e fala de seu portfólio, que inclui Dexco, Banco ABC, Tupy, BrasilAgro e Ternium

For this exciting conversation, I am joined by NanoPalm CEO and co-founder Dr. Ali Alhasan and by Charles River Executive Director Ramin Baghirzade, who joins us to talk about Charles River's incubator program for startups like NanoPalm. Alhasan and his co-founder, Dr. Samar Alsudir, began NanoPalm to help reach rare disease patients who could benefit from advanced gene therapies. NanoPalm is the first company to conduct a gene therapy clinical trial in Saudi Arabia, with plans for many more treatments in the works. Listen now to learn about the trial, Charles River's incubator program, and about the current state of biotech startup in Saudi Arabia.

What if a mouse could help shape the future of cancer treatment? In this episode of Sounds of Science, host Mary Parker speaks with Julia Schüler, DVM, PhD, Research Director and Therapeutic Area Lead for Oncology at Charles River. Julia shares how patient-derived xenograft (PDX) models—often described as “avatars” of human tumors—are transforming preclinical oncology research. From preserving tumor heterogeneity to improving translational relevance, PDX models are accelerating the discovery of more effective, personalized therapies. Tune in as we explore how these advanced models are driving innovation across the drug development pipeline—from target discovery to clinical trial design.Show NotesPDX Tumor Organoids : A New Tool in Drug Discovery Testing Realm Organoids: Some Assembly Required Patient-Derived Xenografts- PDX Models 3D Tumor Models In Vitro PDX Assays 

Today:The Charles River Jazz Festival occurs July 12 at the Herter Park Amphitheater on Soldier's Field Road. More info and and to reserve a free ticket go to BostonJazzFoundation.org. Festival founder Seba Molnar joinswith foundation co-founder Moriah Phillips, and vice-chair Jess Curin. They all perform.And, retired federal judge Nancy Gertner reviews the Supreme Court's end-of-term rulings released today, including limiting orders blocking the Trump administration's birthright citizenship ban.

Join me, Charles River's Miriam Guest, and independent consultant Vanessa Figueroa as we tackle the role of a microbiologist in drug manufacturing. Who is keeping patients safe from contamination, and how are they making sure our life saving drugs are not contaminated? How is manufacturing like yoga? Find out by listening now!

Werewolves and DemonsStory 1In Stone River, a seemingly typical American town with familiar seasonal events like carnivals and Christmas parades, a dark secret sets it apart: strict rules govern residents' lives to protect them from monstrous, bipedal wolf-like creatures that inhabit the surrounding woods and prey on humans. These rules, such as never traveling alone or leaving windows open at night, stem from centuries-old local lore about these creatures, which have claimed numerous lives, including newcomers like E.G. Parker and his crew in the 1940s, and local teens Alan and Lisa in the 1970s, whose gruesome deaths haunt the town. A 63-year-old lifelong resident, recounts the town's history and the rules' origins, which predate his grandmother's tales of a time without them. His own harrowing encounter with one of these creatures, when his truck runs out of gas on a lonely road, nearly costs him his life.Story 2In the summer of 1972, a 14-year-old boy fishing at a lagoon beneath the dilapidated "Monkey Bridge" near the Charles River discovers an old, ornate watch entangled in weeds, which he cleans and cherishes, unaware of its sinister history. That night, a terrifying dream places him on the bridge, reliving the fatal fall of a boy his age, and he awakens to see the boy's ghost pleading for help, with the watch mysteriously stopping at 4:18. The next day, compelled to climb the bridge, he encounters the ghostly boy again, tormented by demonic gremlins who mock him into a deadly crossing, revealing the watch's curse: it lures young boys to their deaths, manipulated by these malevolent entities. With his grandfather's help, a war veteran familiar with such evil, they uncover the watch's connection to Timothy Burns, a boy who drowned decades ago, and destroy it at his grave, banishing the gremlins and freeing the trapped souls. Now an old man and veteran himself, the narrator reflects on the ongoing battle against such soul-stealing evil, which persists in modern times through technology, as he vigilantly protects his grandson from similar unseen dangers.Become a supporter of this podcast: https://www.spreaker.com/podcast/what-if-it-s-true-podcast--5445587/support.

In this episode, Aniket Bhardwaj, Vice President at Charles River Associates, shares insights on the growing role of cybersecurity in business and national security. 

If you see Christine by the Charles River trying to sell you on eternal life... no you didn't.Join our not so secret labor force! https://www.patreon.com/beachtoosandyWe have merch! https://www.beachtoosandy.storeXandy's stream: twitch.tv/xandyschieferWatch clips of your favorite moments! https://www.youtube.com/beachtoosandywatertoowetWatch videos from our episodes on TikTok! https://tiktok.com/@beachtoosandyXtine's Etsy: https://www.etsy.com/shop/thextinefiles Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

If you see Christine by the Charles River trying to sell you on eternal life... no you didn't. Join our not so secret labor force! https://www.patreon.com/beachtoosandy We have merch! https://www.beachtoosandy.store Xandy's stream: twitch.tv/xandyschiefer Watch clips of your favorite moments! https://www.youtube.com/beachtoosandywatertoowet Watch videos from our episodes on TikTok! https://tiktok.com/@beachtoosandy Xtine's Etsy: https://www.etsy.com/shop/thextinefiles Learn more about your ad choices. Visit megaphone.fm/adchoices